Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Bee Venom and Spiramycin Reduce Parasite Burden in Mice With Toxoplasmosis

3 days ago 11

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A combination treatment pairing bee venom with spiramycin achieved a 96 percent reduction in tachyzoite counts in mice infected with acute toxoplasmosis, outperforming single-agent therapies. The experimental findings demonstrate that bee venom possesses measurable therapeutic potential against acute infection caused by the virulent RH strain of Toxoplasma gondii, particularly when administered alongside the conventional antimicrobial agent spiramycin.

Acute toxoplasmosis presents a critical medical challenge because the infection can produce severe complications, while currently available pharmacological regimens are frequently accompanied by adverse effects. Bee venom has been recognized for its potential antiparasitic and immunomodulatory properties, yet its therapeutic capacity to counteract acute toxoplasmosis, particularly in combined administration with spiramycin, had previously remained insufficiently investigated in controlled experimental settings.

To evaluate these therapeutic responses, researchers established an in vivo model of experimental acute toxoplasmosis using Swiss albino mice. Acute infection was induced through inoculation with the virulent Toxoplasma gondii RH strain. Following the establishment of infection, the animals received different therapeutic regimens comprising bee venom alone, spiramycin alone, or a combined administration of bee venom and spiramycin to compare therapeutic performance against untreated infected control animals.

Therapeutic efficacy was systematically monitored across multiple parasitological, histological, and molecular parameters. The investigators assessed parasitic burden by calculating quantitative tachyzoite counts retrieved from the peritoneal fluid of the mice. In parallel, tissue sections were prepared from the liver and lungs of the experimental subjects to examine histopathological alterations, while real-time polymerase chain reaction assays measured changes in circulating serum microRNA levels.

Parasitological evaluations revealed that while the various treatment regimens demonstrated varying degrees of therapeutic efficacy, the dual regimen combining bee venom and spiramycin yielded the most pronounced therapeutic benefit. This combined intervention produced the greatest reduction in peritoneal tachyzoite counts, lowering parasite concentrations by 96 percent relative to the untreated infected mice, indicating significant antiparasitic cooperative action between the natural compound and the established pharmaceutical agent.

Molecular profiling demonstrated substantial shifts in circulating epigenetic markers during acute infection and subsequent recovery. Induction of acute toxoplasmosis was associated with a 24.47-fold increase in the serum expression of mmu-miR-712-3p and an 83.64-fold increase in mmu-miR-146b-5p expression. Therapeutic intervention significantly decreased the expression levels of both microRNAs, with the most marked reductions recorded in the cohort receiving combined bee venom and spiramycin.

Microscopic examination of vital organ tissues confirmed corresponding structural improvements following the therapeutic interventions. Untreated infection caused notable hepatic and pulmonary damage, whereas treated animals exhibited marked improvements in liver and lung lesions. Paralleling the parasitological and molecular outcomes, the most pronounced histological amelioration occurred in the cohort treated with the combination of bee venom and spiramycin.

The study authors conclude that bee venom exhibits promising therapeutic potential against acute experimental toxoplasmosis, functioning effectively as an individual therapy and yielding superior outcomes when combined with spiramycin. Furthermore, the notable modulation of serum mmu-miR-712-3p and mmu-miR-146b-5p expression warrants continued investigation to clarify their specific biological roles in host infection responses and their potential utility as circulating indicators of treatment response.

Subject of Research: Evaluation of bee venom and spiramycin treatments in experimental murine acute toxoplasmosis

Article Title: Therapeutic and Epigenetic Effects of Bee Venom on Acute Toxoplasmosis in Mice: A Parasitological, Histopathological, and MicroRNA Analysis

Article References: Moubarak, M. A., Abdelmaksoud, H. F., Shaker, M. H., Zalat, R. S., Hassan, M., ElSherbini, M. S., & Ismail, M. A. M. (2026). Therapeutic and Epigenetic Effects of Bee Venom on Acute Toxoplasmosis in Mice: A Parasitological, Histopathological, and MicroRNA Analysis. Acta Parasitologica, 71(6), Article 261. https://doi.org/10.1007/s11686-026-01426-7

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01426-7

Keywords: acute toxoplasmosis, bee venom, spiramycin, Toxoplasma gondii, RH strain, Swiss albino mice, tachyzoite counts, peritoneal fluid, parasite burden, mmu-miR-712-3p, mmu-miR-146b-5p, microRNA expression, real-time PCR, hepatic lesions, pulmonary lesions, histopathology, antiparasitic activity, immunomodulatory properties

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway